Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.57 |
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130164 | 0.89 | TBXA2R (0.81) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9754552 | 0.88 | MEN1 (0.84) | TBXA2RMEN1KMT2AALDH1A1PRMT1 | |
| SCHEMBL9126335 | 0.87 | TBXA2R (0.78) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11119146 | 0.87 | TBXA2R (0.77) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL10461554 | 0.87 | TBXA2R (0.76) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15078819 | 0.87 | TBXA2R (0.81) | TBXA2RALDH1A1MAPTPRMT1AKR1C3 | |
| Daltroban SCHEMBL9661107 | 0.86 | TBXA2R (0.74) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9131948 | 0.86 | TBXA2R (0.76) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9130060 | 0.86 | TBXA2R (0.75) | TBXA2RMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL11108980 | 0.86 | TBXA2R (0.75) | TBXA2RMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2025-05-08 | — | — | US | claimed |
| US-12178834-B2 | Treating myelin diseases with optimized cell preparations | UNIVERSITY OF ROCHESTER (US) | 2024-12-31 | — | — | US | claimed |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| EP-4244341-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | Akttyva Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2023-03-23 | — | — | US | claimed |
| US-11596700-B2 | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder | UNIVERSITY OF ROCHESTER (US) | 2023-03-07 | — | — | US | claimed |
| US-20220273728-A1 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS | UNIV ROCHESTER (US) | 2022-09-01 | — | — | US | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2020-12-31 | — | — | US | claimed |
| US-4900723-A | Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination | E. R. SQUIBB & SONS, INC. (US) | 1990-02-13 | — | — | US | claimed |
| EP-0351755-A1 | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0340008-A1 | Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination | E.R. SQUIBB & SONS, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0337697-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for treating pulmonary hypertension caused by protamine induced neutralization of hepamin | E.R. SQUIBB & SONS, INC. (US) | 1989-10-18 | — | — | EP | claimed |
| EP-0332306-A2 | Preventing platelet loss using a thromboxane A2 receptor antagonist | E.R. Squibb & Sons, Inc. (US) | 1989-09-13 | — | — | EP | claimed |
| US-4857548-A | Method of preventing or reducing platelet loss during extracorporeal circulation using a thromboxane A2 receptor antagonist | E. R. SQUIBB & SONS, INC. (US) | 1989-08-15 | — | — | US | claimed |
| EP-0320935-A2 | Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist | E.R. Squibb & Sons, Inc. (US) | 1989-06-21 | — | — | EP | claimed |
| EP-0309801-A2 | Use of thromboxane A2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction | E.R. Squibb & Sons, Inc. (US) | 1989-04-05 | — | — | EP | claimed |
| US-4808627-A | Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist | E. R. SQUIBB & SONS, INC. (US) | 1989-02-28 | — | — | US | claimed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885MEN1 1012/4885KMT2A 2296/4885 |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885MEN1 1012/4885KMT2A 2296/4885 |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885MEN1 1012/4885KMT2A 2296/4885 |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | TBXA2R 1/4885MEN1 1012/4885KMT2A 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.